Hoth Therapeutics (HOTH) News Today $1.58 -0.09 (-5.39%) Closing price 04:00 PM EasternExtended Trading$1.58 -0.01 (-0.32%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOTH Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Hoth Therapeutics stock rises after expanding AI initiative with NVIDIAOctober 9 at 3:27 AM | za.investing.comHoth Therapeutics shares climb after expanding AI partnership with NVIDIAOctober 9 at 3:27 AM | msn.comHoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise PlatformOctober 8 at 8:02 AM | prnewswire.comHoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025October 7 at 7:57 AM | prnewswire.comHoth Therapeutics, Inc. (HOTH) Files EMA Application for Global Expansion of HT-001 Skin TherapySeptember 25, 2025 | finance.yahoo.comHoth Therapeutics expands intellectual property portfolio for HT-001September 25, 2025 | msn.comHoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin ToxicitiesSeptember 24, 2025 | prnewswire.comHoth Therapeutics, Inc. (HOTH) Files EMA Application for Global Expansion of HT-001 Skin TherapySeptember 23, 2025 | insidermonkey.com15 Best Biotech Penny Stocks to Invest in Right NowSeptember 21, 2025 | insidermonkey.comHoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company HistorySeptember 16, 2025 | prnewswire.comHoth Therapeutics, Inc.: Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi ...September 10, 2025 | finanznachrichten.deHoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin ToxicitiesSeptember 10, 2025 | prnewswire.com3 Under-the-Radar Biotechs Under $5 That Could Soar 200%3 biotech stocks under $5 with cancer, obesity, and psychedelic therapies offer speculative investors high-risk, high-reward potential: HOTH, SILO, and ANIX.September 9, 2025 | marketbeat.comHoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug DevelopmentSeptember 4, 2025 | prnewswire.comHoth Therapeutics stock soars on positive preclinical data for cancer drugSeptember 3, 2025 | za.investing.comHoth Therapeutics, Inc.: Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results ...September 2, 2025 | finanznachrichten.deEXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven CancersSeptember 2, 2025 | finance.yahoo.comHoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory ...September 2, 2025 | finance.yahoo.comHoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory StandardsSeptember 2, 2025 | prnewswire.comHoth Therapeutics Renews CEO Contract Amidst Patent FilingAugust 22, 2025 | msn.comHoth Therapeutics Holds Annual Shareholder MeetingAugust 11, 2025 | theglobeandmail.comHoth Therapeutics, Inc.: Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in EuropeJuly 29, 2025 | finanznachrichten.deHoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in EuropeJuly 29, 2025 | prnewswire.comHoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide BeginsJuly 22, 2025 | prnewswire.comHOTH THERAPEUTICS INC - FinanzNachrichten.deJune 26, 2025 | finanznachrichten.deHoth Therapeutics says HT-001 met primary endpoint in CLEER-001 studyJune 26, 2025 | finance.yahoo.comHoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.June 25, 2025 | prnewswire.comHoth Therapeutics stock rises after positive Phase 2a trial resultsJune 24, 2025 | investing.comHoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side EffectsJune 24, 2025 | prnewswire.comHoth Therapeutics to host KOL Event Spotlighting HT-001, Novel TherapyJune 23, 2025 | prnewswire.comHoth Therapeutics, Inc.: Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity ...June 20, 2025 | finanznachrichten.deHoth Therapeutics, Inc.: Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward GrowthJune 19, 2025 | finanznachrichten.deHoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward GrowthJune 18, 2025 | prnewswire.comHoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND PathwayJune 18, 2025 | prnewswire.comHoth Therapeutics to Attend 2025 BIO International ConventionJune 16, 2025 | prnewswire.comHoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell DiseasesJune 12, 2025 | prnewswire.comHoth Therapeutics, Inc.: Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin ToxicitiesJune 11, 2025 | finanznachrichten.deHoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin ToxicitiesJune 11, 2025 | prnewswire.comHoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin ToxicitiesJune 5, 2025 | prnewswire.comHoth Therapeutics reports promising HT-KIT preclinical resultsMay 13, 2025 | investing.com/C O R R E C T I O N -- Hoth Therapeutics, Inc./May 12, 2025 | gurufocus.com/C O R R E C T I O N -- Hoth Therapeutics, Inc./ | HOTH Stock NewsMay 12, 2025 | gurufocus.comHoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven CancersMay 12, 2025 | prnewswire.comCutaneous Lupus Erythematosus Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and CompaniesMay 6, 2025 | theglobeandmail.comHoth Therapeutics confirms patent application fee paymentMay 3, 2025 | investing.comHoth Therapeutics’ HT-001 shows efficacy in Phase 2a pruritus trialApril 17, 2025 | markets.businessinsider.comHoth Therapeutics granted Japanese patent for novel RNA-based cancer therapyApril 17, 2025 | markets.businessinsider.comHoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology PlatformApril 17, 2025 | prnewswire.comHoth Therapeutics reports interim data from Phase IIa trial of HT-001 for pruritusApril 17, 2025 | msn.comHoth Therapeutics, Inc.: Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical TrialApril 15, 2025 | finanznachrichten.de Get Hoth Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Videos HOTH Media Mentions By Week HOTH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HOTH News Sentiment▼0.410.77▲Average Medical News Sentiment HOTH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HOTH Articles This Week▼62▲HOTH Articles Average Week Get the Latest News and Ratings for HOTH and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Hoth Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Prelude Therapeutics News Invizyne Technologies News Connect Biopharma News Vaxart News Coeptis Therapeutics News Unicycive Therapeutics News CervoMed News XBiotech News Equillium News Repare Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HOTH) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenIf you're a futures trader (or want to be one), this could be the biggest shift you'll ever see in the prop fi...Neuro Street Trading Academy | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe 7 Warning Signals Flashing Red Right NowA free report revealing the 7 key indicators that have predicted every major economic collapse since 1929. ...American Alternative | Sponsored"I'm risking my reputation on this"If I'm right about what's coming, this could be the most important book you'll read this yearCrypto 101 Media | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hoth Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hoth Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
